Transcatheter Arterial Embolization With Spherical Embolic Agent for Pulmonary Metastases From Renal Cell Carcinoma

Seki, Akihiko; Hori, Shingo; Sueyoshi, Satoru; Hori, Akihiro; Kono, M; Murata, Shinichi; Maeda, Masahiko

doi:10.1007/s00270-013-0576-4

Cited by 24 publications

(22 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…found that three sessions of BACE with SAP‐MS lowered the ECOG‐PS score from 3 to 0 in a patient with a large lung cystic adenocarcinoma . Furthermore, several studies have confirmed that BACE with SAP‐MS did not increase the rate of SAEs . BACE combined with SAP‐MS or DEB was therefore associated with a better performance status.…”

Section: Discussionmentioning

confidence: 93%

“…Seki et al . found that BACE with SAP‐MS was associated with ORRs of 38.8%, 44.9%, and 38.8% after 1, 3, and 6 months, respectively, in patients with unresectable pulmonary metastases from renal cell carcinoma . Thus, DEB‐BACE is a feasible treatment option for patients with lung cancer refractory to standard treatment.…”

Section: Discussionmentioning

confidence: 99%

“…Seki et al . conducted a retrospective study of 16 patients with unresectable pulmonary metastases from renal cell carcinoma who were treated by BACE with superabsorbent polymer microspheres (SAP‐MS), and found objective response rates (ORRs) of 38.8%, 44.9%, and 38.8% after 1, 3, and 6 months, respectively . Kennoki et al .…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The efficacy of drug‐eluting beads bronchial arterial chemoembolization loaded with gemcitabine for treatment of non‐small cell lung cancer

Bie

et al. 2019

Thoracic Cancer

View full text Add to dashboard Cite

Background Drug‐eluting beads bronchial arterial chemoembolization (DEB‐BACE) can embolize the tumor‐feeding artery and also be loaded with antitumor drugs, which can be released slowly into the local tumor environment. The effect of DEB‐BACE in patients with lung cancer remains unclear. We evaluated the efficacy and safety of DEB‐BACE with gemcitabine‐loaded CalliSpheres beads in patients with non‐small cell lung cancer (NSCLC). Methods From May 2017 to December 2018, six patients with NSCLC who were ineligible or refused to receive standard treatment underwent DEB‐BACE with gemcitabine‐loaded CalliSpheres beads. The primary endpoint was the objective response rate (ORR). The secondary endpoints were progression‐free survival (PFS), overall survival (OS), and quality of life. Safety was evaluated by the occurrences of adverse events and serious adverse events. Results All patients were treated with DEB‐BACE loaded with gemcitabine (800 mg) using CalliSpheres beads. Five patients also received transarterial infusion with nedaplatin (80–100 mg). Of the six patients, five underwent a second session of DEB‐BACE, with intervals of one month between the first and second session. The median follow‐up time was 16.5 months (7.0–23.0 months). ORR and disease control rate were 50.0% and 100.0%, 50.0% and 83.3%, 50.0% and 66.7% respectively at 2, 4, and 6 months after DEB‐BACE. One patient maintained a partial response and the other five had progressive disease, of whom two patients died and the other three remained alive receiving targeted therapy, radiotherapy, transarterial infusion or thermal ablation. The median PFS was 8.0 months (4–23 months), and the 6‐ and 12 month PFS rates were 66.7% and 16.7%, respectively. The median OS was 16.5 months (7–23 months), and the six and 12 month OS rates were 100.0% and 66.7%, respectively. Hemoptysis, cough and dyspnea disappeared after DEB‐BACE in four patients. Global quality of life, physical and emotional functioning were all significantly improved at two months (P < 0.05). There were no serious adverse events. Conclusions DEB‐BACE with gemcitabine‐loaded CalliSpheres beads is a feasible and well‐tolerated treatment for patients with NSCLC who are ineligible or refuse to receive standard treatment.

show abstract

Section: Discussionmentioning

confidence: 93%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The efficacy of drug‐eluting beads bronchial arterial chemoembolization loaded with gemcitabine for treatment of non‐small cell lung cancer

Bie

et al. 2019

Thoracic Cancer

View full text Add to dashboard Cite

show abstract

“…A mean of 2.8 treatments per patient was performed. As seen with RCC mets treated with bland embolization [8], response correlated with degree of iodized oil enhancementpartial response in 35%, stable disease in 26% and progression in 39%.…”

Section: Tpce To Achieve Tumor Regressionmentioning

confidence: 80%

“…Seki et al performed particle embolization of 49 lesions caused by renal cell carcinoma (RCC) (22 pulmonary nodules, 17 mediastinal nodes, and 10 hilar nodes) in 16 patients over 1 to 5 sessions. 8 In these cases, the authors described the use of small particles to achieve a therapeutic, bland embolization. Bronchial arteries were embolized in almost all patients (87.5%) and nonbronchial feeders were included in the majority.…”

Section: Bland Tae To Achieve Tumor Regressionmentioning

confidence: 99%

Embolization of Chest Neoplasms: The Next Frontier in Interventional Oncology?

Lorenz

Navuluri

2019

Semin intervent Radiol

View full text Add to dashboard Cite

The management of chest tumors and their sequelae has been an uncommon indication for transarterial embolization (TAE). More recently, vascular embolization has been increasingly performed for this indication. The most common reported indication for embolization of neoplastic disease in the chest is the control of bleeding resulting either from iatrogenic causes or from tumor invasion into a bronchus or vessel.A natural extension of the application of TAE to neoplasm-related hemoptysis is its burgeoning indication as a possible primary treatment for benign chest tumors, primary lung neoplasms, and metastatic disease in patients that are refractory to systemic therapies and have limited or no surgical options. The goals for this indication are tumor regression and management of bulk-related symptoms. In addition to bland TAE for this indication, authors have reported very initial results applying transarterial chemoembolization (TACE) and transarterial radioembolization (TARE) to chest neoplasms with promising results that support feasibility and safety. This article is an up-to-date review of the management of chest tumors with embolization and its variants.

show abstract

Embolization for Lung Tumors

Boas

2024

Interventional Oncology

View full text Add to dashboard Cite

Transcatheter Arterial Embolization With Spherical Embolic Agent for Pulmonary Metastases From Renal Cell Carcinoma

Abstract: TAE with SAP-MS might be a well-tolerated and locally efficacious palliative option for patients with pulmonary metastases from RCC.

Cited by 24 publications

References 21 publications

The efficacy of drug‐eluting beads bronchial arterial chemoembolization loaded with gemcitabine for treatment of non‐small cell lung cancer

The efficacy of drug‐eluting beads bronchial arterial chemoembolization loaded with gemcitabine for treatment of non‐small cell lung cancer

Embolization of Chest Neoplasms: The Next Frontier in Interventional Oncology?

Embolization for Lung Tumors

Contact Info

Product

Resources

About